OIS Retina Innovation Summit banner

Major Sponsors


Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.


Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Supporting Sponsors


At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system.


For more than 30 years D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. has worked intensively with leading top surgeons. Therefore at D.O.R.C. we know exactly which requirements instruments and equipment must satisfy. Our knowledge, combined with a unique mix of talent for the development of new ideas, high design quality and a strong product philosophy, results in highly innovative products.

Outlook Therapeutics

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.


REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.

Innovation Sponsors


Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.

Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders.


Eyevensys is a Clinical stage company developing an innovative non-viral gene therapy platform targeting eye indications.

Eyevensys has developed a proprietary electro-transfection delivery system which can administer proprietary plasmids able to deliver sustained proteins to the back of the eye. The technology involves a minimally invasive procedure which will lead to better safety, compliance and clinical outcome.

The primary targeted indication of interest is Wet AMD.

The second targeted indication is geographic atrophy, the late stage of Dry AMD with an upside in Retinitis pigmentosa and glaucoma.

The technology developed has been evaluated and validated for its feasibility and safety in a safety phase 1 clinical trial, in 18 patients with late stage non-infectious uveitis.

Eyevensys has a strong management team with extensive clinical ophthalmology drug development expertise and gene therapy from Big Pharma.

Eyevensys has also partnered with two key manufactures for the platform, in USA, Phillips Medisize and Minnetronnix medical.

The company is ready to launch its series C and also looking for co-development /partnerships opportunities.


Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.


Opthea Limited (NASDAQ: OPT; ASX: OPT) is a public biotechnology company developing OPT-302, a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea is currently conducting two concurrent Phase 3 clinical trials with OPT-302 which are actively recruiting and enrolling treatment-naïve patients for the treatment of wet AMD.


RetinAI Medical AG (RetinAI) develops software solutions to accelerate and optimise clinics, research and pharmaceutical workflows, making eye health institutions more efficient with insights and knowledge extracted from data. The company builds software solutions to collect, organize and analyze health data from the clinic level, all the way to pharma, empowering communities of healthcare professionals & patients with data analysis.

RetinAI pioneers a software that, based on evidence and data, enables the right decisions sooner in healthcare and provides certified solutions to pharma, research and clinics alike. RetinAI Discovery® is a CE-Marked and FDA-cleared medical image and data platform, cloud-based, that digests and harmonise at-scale volumes of data. Thanks to proprietary AI models, Discovery enables precision analysis and transfer of medical data linked to the patient, connecting devices, data sources & decisions in a seamless and easy manner.
Discovery is the workbench for healthcare professionals throughout the entire journey of the disease, easing diagnosis and optimizing analysis for better care at every step.


Rezolute is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases. We take novel approaches to defined disease pathways and leverage our metabolic expertise to develop therapies that have the potential to overcome the shortcoming of current standards of care by significantly improving clinical outcomes for patients.

Media Partners



get the latest news & exclusive content!

get the latest news & exclusive content!